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The kinetics of intrahepatic hepatitis C virus (HCV)–specific CD4+ T cell responses and their role in progression
of fibrosis have not previously been characterized. Subjects with HCV/Schistosoma mansoni coinfection have
a more rapid progression of HCV liver fibrosis than do those with HCV infection alone. The present prospective
longitudinal study compared the liver histology, HCV-specific intrahepatic and peripheral CD4+ T cell pro-
liferative responses, and cytokines (enzyme-linked immunospot) in 48 subjects with unresolved acute HCV
infection with or without S. mansoni coinfection, at 6–10 months after acute infection and at the end of
follow-up ( months), and the findings were correlated to the rate of progression of fibrosis per year.96 8.7
Coinfected subjects had significant worsening of fibrosis, compared with subjects with HCV infection alone.
At baseline, subjects with HCV infection alone had stronger multispecific intrahepatic HCV-specific CD4+ T
helper 1 responses than did coinfected subjects, who had either no responses or weak, narrowly focused
responses, and, over time, these T cell responses were maintained only in the liver. The rate of progression
of fibrosis and virus load inversely correlated with intrahepatic HCV-specific CD4+ T cell response. The present
prospective analysis indicates that enhancement of progression of liver fibrosis is associated with failure to
develop early, multispecific, HCV-specific CD4+ Th1 responses, suggesting that novel therapeutic approaches
inducing strong cellular immune responses might limit subsequent liver damage in individuals with chronic
hepatitis C.
Hepatitis C virus (HCV) is a major causative agent
of chronic hepatitis, and it is estimated that 170–200
million people are infected worldwide [1]. In the
United States, nearly 2% of the population is infected,
whereas, in countries such as Egypt, the prevalence of
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HCV infection is 10%–31% [2, 3]. Approximately 70%
of infected persons develop chronic hepatitis C, and
20%–30% may develop cirrhosis [4–6]. There is little
evidence that progression of liver disease is significantly
affected by virologic factors, including virus load, viral
genotype, and quasi-species diversity [5–7]. However,
many host factors have been observed to increase the
risk of progression of liver disease, including male sex,
older age at infection, and immunosuppressed states,
such as HIV infection [5–8].
Studies have shown that spontaneous resolution of
acute hepatitis is associated with vigorous and persistent
HCV-specific CD4+ Th1 and CD8+ cytotoxic T cell re-
sponses [9–12]. However, the role of these cellular im-
mune responses, particularly in the liver, once chronic
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Table 1. Demographic and clinical characteristics of subjects at baseline.
Parameter
Group A:
HCV infection alone
Group B:
HCV/S. mansoni
coinfection
Control:
S. mansoni
infection alone
No. 23 25 20
M:F 14:9 15:10 12:8
Age, mean  SD, years 36.6  8.1 34.2  7.6 31.7  2.9
Risk factors for HCV transmission
Occupational exposure 20 22 NA
Blood transfusion 1 2 NA
Injection drug use 2 0 1
Surgery 0 1 2
ALT level, mean  SD, U/L 144.3  62.5 168.4  75.1 23  9.7
AST level, mean  SD, U/L 108.6  43.3 112.5  37.6 20  4.6
g-GT level, mean  SD, U/L 72.5  23.5 89.4  18.2 46.1  2.4
Total bilirubin, mean  SD, mg/dL 2.8  1.1 3.4  0.65 0.8  0.2
RNA titer, mean  SD, copies  105/mL 12.3  3.5a 21.3  4.6a NA
NOTE. Group A, 23 subjects with chronic hepatitis C virus (HCV) infection alone; group B, 25 subjects with chronic
HCV/Schistosoma mansoni coinfection. The control group comprised 20 subjects with S. mansoni infection alone. ALT,
alanine transaminase; AST, aspartate transaminase; GT, glutamyl transferase; NA, not applicable.
a , group A vs. group B (Wilcoxon signed rank test).P ! .01
infection is established, is less clear, since the natural history
of HCV is highly variable and occurs over the course of decades.
We and others have demonstrated that subjects coinfected
with HCV and Schistosoma mansoni, a parasite that induces a
shift in the T helper response toward a Th2 profile [13–15],
show increased rates of chronic evolution and accelerated pro-
gression of liver disease, compared with subjects with HCV
infection alone [11, 16, 17]. Given the more-rapid progression
of liver disease in these subjects, HCV/S. mansoni coinfection
represents a useful model for examination of the relationship
of the immune response and subsequent liver injury. In a
smaller cohort of subjects with acute HCV infection and with-
out S. mansoni infection, we have previously shown that HCV-
specific CD4+ Th1 responses in peripheral blood mononuclear
cells (PBMCs) were associated with a more favorable disease
outcome [11]. In the present prospective longitudinal study,
we addressed the following issues: (1) do the characteristics and
kinetics of the intrahepatic HCV-specific CD4+ T cell responses
differ between subjects with HCV infection alone and subjects
with coinfection and, if so, (2) do the intrahepatic HCV-specific
CD4+ T cell responses correlate with the rates of progression
of fibrosis? To answer these questions, we characterized the
HCV-specific CD4+ T cell responses in the liver and peripheral
blood at an early phase of chronic HCV infection (6–10 months
after acute HCV infection) and then 8 years later, in subjects
with and without S. mansoni coinfection, and correlated these
responses with the progression of liver disease.
SUBJECTS, MATERIALS, AND METHODS
Study population. The study cohort comprised 48 subjects
(table 1) who failed to clear viremia after acute HCV infection.
Baseline blood and liver samples were obtained 6–10 months
after acute HCV infection, and subjects were followed pro-
spectively for 90–112 months (mean  SD, months).96 8.7
The diagnosis of acute HCV infection was based on an in-
crease of serum alanine aminotransferase (ALT) levels to 110
times above the upper limit of normal, seroconversion from
anti-HCV–negative to anti-HCV–positive antibody status (as
determined by use of second-generation ELISA [Abbott Lab-
oratories]), and positive polymerase chain reaction results for
HCV RNA (Amplicor; Roche Diagnostics). The majority of
subjects were health-care workers who had had HCV-negative
serum specimens archived before exposure and who reported
occupational exposure to HCV. Subjects were further classified
according to S. mansoni status into the following groups: 23
subjects with HCV infection alone (group A) and 25 subjects
with HCV/S. mansoni coinfection (group B). Schistosomiasis
was diagnosed by history, detection of S. mansoni ova in stools
(modified Kato test), or rectal biopsy; seropositivity to schis-
tosomal antibodies (indirect hemagglutination; Femouz Lab-
oratories); and evidence of schistosomiasis on liver biopsy spec-
imens. Other causes of hepatitis were ruled out by history and
appropriate serological studies. No subject had received anti-
viral or immunomodulatory treatment before entry or during
follow-up. Groups were matched according to age, sex, and
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route and duration of HCV infection (6–10 months). All sub-
jects had genotype 4 infection, as determined by a second-
generation reverse-hybridization line-probe assay (Inno-LiPA
HCV II; Innogenetics). Twenty subjects with proven hepatic
schistosomiasis and comparable duration of S. mansoni infec-
tion were enrolled as a control group and prospectively fol-
lowed. PBMCs and liver tissue from 10 subjects who underwent
a biopsy during abdominal surgery or laparoscopy due to sus-
pected liver disease, but for whom histological diagnosis re-
vealed a healthy liver, served as a control for liver-infiltrating
lymphocyte (LIL) proliferative and ELISPOT assays.
All subjects participating in the present study presented writ-
ten, informed consent before any study-related procedures were
performed. The protocol and all study procedures were re-
viewed and approved by the Institutional Ethics Committee of
the Ain Shams University and the Beth Israel Deaconess Med-
ical Center and were conducted in conformity with the ethical
guidelines of the Declaration of Helsinki and with the human-
experimentation guidelines of the US Department of Health
and Human Services.
Histological assessment Paired liver biopsy specimens, ob-
tained from all study subjects at baseline (6–10 months after
acute HCV infection) and at the end of follow-up (mean 
SD, months), were read under code by 2 pathologists96 8.7
in a blinded manner, without knowledge of the clinical data or
the chronology of the biopsies, adopting the scoring system
proposed by Ishak et al. [18], which includes a grading score
that evaluates the necroinflammatory activity (score, 0–18) and
a fibrosis score of 0 (no fibrosis) to 6 (cirrhosis). Moreover,
biopsy specimens were assessed for morphologic features of
schistosomiasis—such as S. mansoni ova, eosinophils, granu-
loma, pigment, and fibrosis of pipe stem type—by pathologists
experienced in the interpretation of such features [16].
The direct rate of progression of fibrosis was assessed by the
difference in fibrosis scores between baseline and follow-up liver
biopsies, divided by the duration of time between the biopsies,
and expressed as fibrosis units per year. For example, for a
subject with fibrosis stage 2 at the first biopsy and stage 3 at
the second biopsy, performed 2 years later, the rate of pro-
gression of fibrosis was 0.500 fibrosis units/year.
Cell preparation. Blood samples were obtained at entry
and at the same days that the baseline biopsy and the follow-
up biopsy were performed. PBMCs from study and control
subjects were isolated immediately by use of Ficoll-Hypaque
(Sigma) density gradient centrifugation, as described elsewhere
[11, 13]. For isolation of mononuclear cells from liver tissue,
freshly recovered excess liver tissue not needed for diagnostic
purposes was washed extensively with PBS to remove contam-
inating blood and then was sieved and pipetted vigorously
through a needle. These procedures produced optimal yields of
viable intrahepatic lymphocytes ( 1 cells/biopsy speci-55.5 10
men). CD4+ liver-infiltrating lymphocytes were expanded from
liver biopsy specimens, as described elsewhere [19], by use of
anti-CD3 antibody (Immunotech). Phenotypic analysis of liver-
infiltrating lymphocytes was performed by monoclonal antibody
staining of intrahepatic lymphocytes and analysis on a FACScan
flow cytometer with CellQuest software (Becton Dickinson). Cry-
opreserved PBMCs and LILs were used in all assays.
HCV and control antigens. Purified recombinant HCV
proteins (HCV core [aa 2–120]; NS3 [aa 1192–1457]; NS4 [aa
1569–1931]; and NS5 [aa 2054–2995]) derived from the HCV-
1 prototype sequence were purchased from Chiron. All antigens
were expressed as COOH-terminal fusion proteins with human
superoxide dismutase (SOD) in yeast; therefore, yeast and SOD
were used as controls for nonspecific stimulation in prolifer-
ation and ELISPOT assays. Soluble egg antigen (SEA) and sol-
uble adult worm antigen (SWAP) were prepared as described
elsewhere [13]. Phytohemoagglutinin (PHA; 5 mg/mL at 1:200
dilution; Murex Diagnostics) and tetanus toxoid (TT: 1 mg/mL;
Wyeth Laboratories) were used as positive controls.
HCV-specific CD4+ proliferative T cell assays. Prolifera-
tion assays were performed for all study and control subjects
by use of PBMCs ( ) or LILs ( cells/well, cocul-5 42 10 2 10
tured with irradiated autologous PBMCs as antigen-51 10
presenting cells), as described elsewhere [11, 13], by use of the
HCV proteins described above (at concentrations of 2 mg/mL),
schistosomal antigens (SEA, 15 mg/mL; SWAP, 50 mg/mL), and
control antigens. All values were obtained in triplicate. A stim-
ulation index (SI) of 3 (3 SD above the mean SI of healthy
control subjects) was considered to be significant. The cutoff
for positive CD4+ proliferation for LILs was determined in
comparison to control LILs from livers of HCV-negative sub-
jects. CD4+ and CD8+ depletion assays, performed as described
elsewhere [10, 19], using paramagnetic microbeads conjugated
to a monoclonal mouse anti–human anti-CD8+ or anti-CD4+
antibody (Micro Beads; Miltenyl Biotec), clearly showed that
these are CD4+ T cell responses (data not shown). Neither
subjects infected with S. mansoni alone nor healthy control
subjects had significant responses to any HCV-specific antigen.
No subjects infected with HCV alone had significant responses
to any schistosomal antigen.
ELISPOT assay. ELISPOT and proliferation assays were
performed at the same time for early and late samples, from
an individual subject. ELISPOT assays were performed as de-
scribed elsewhere [19–21], by use of PBMCs (200,000 cells/
well) or intrahepatic lymphocytes ( LILs/well, cocultured42 10
with autologous irradiated [3000 rad] PBMCs) in triplicate,
together with HCV proteins (2 mg/mL), schistosomal proteins
(SEA and SWAP), positive control (PHA, 5 mg/mL; TT, 1 mg/
mL), SOD, yeast stimulation, and medium as negative control.
All assays were counted on an automated ELISPOT reader (AID).
The background was always !15 spot-forming cells (sfcs)/106
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Figure 1. Liver histological assessment and progression of fibrosis in subjects with HCV infection alone and subjects with coinfection. Left panel,
Comparison of the necroinflammatory scores at baseline biopsies (biopsy 1, performed 6–10 months after acute hepatitis) and follow-up, in 23 subjects
with HCV infection alone (black bars), 25 coinfected subjects (white bars), and 20 control subjects with Schistosoma mansoni infection alone (shaded
bars). Bars represent means, and lines represent SD. Middle panel, Fibrosis scores at baseline biopsies and follow-up biopsies. At baseline liver
biopsies, subjects with HCV infection alone, coinfected subjects, and control subjects had no fibrosis (stage 0). Coinfected subjects had significantly
greater increases in fibrosis scores detected in follow-up biopsies, compared with subjects with HCV infection alone ( ). Right panel, Rates ofP ! .001
progression of fibrosis (fibrosis units per year). The rate of liver progression of fibrosis was significantly higher in coinfected subjects than in subjects
with HCV infection alone ( in the HCV/S. mansoni coinfected group vs. in the HCV-monoinfected group; ).0.58 0.13 0.1 0.06 P 1 .001
Table 2. Progression of fibrosis in groups of patients and in control subjects.
Characteristic
Group A:
HCV infection alone
(n p 23)
Group B:
HCV/S. mansoni
coinfection
(n p 25)
Pa, group A
vs. group B
Control:
S. mansoni
infection alone
(n p 20)
Pa, group B
vs. control group
Interval between the 2 biopsies, mean, years 8.2 8.3 .89 8.5 .91
Subjects with progression 2 (8.6) 25 (100) !.0001 2 (10) !.0001
No change 21 (91) 0 !.0001 18 (90) .001
Progression, fibrosis score
1 point 1 (4.3) 0 !.0001 2 (10) !.0001
2 points 1 (4.3) 3 (12) .001 0 !.0001
3 points 0 9 (36) !.0001 0 !.0001
13 points 0 13 (52) !.0001 0 !.0001
NOTE. Data are no. (%) of subjects, unless otherwise noted. HCV, hepatitis C virus; S. mansoni, Schistosoma mansoni.
a Determined by use of Fisher’s exact test.
cells. Responses were considered to be positive if the number
of spots per well minus the background was at least 30 sfcs/
106 cells. In all experiments, stimulation with PHA and TT
induced similar numbers of interferon (IFN)–g, interleukin
(IL)–4, and IL-l0 sfcs in both groups of patients, thus indicating
that the capacity of T cells from all subjects to produce these
cytokines is preserved (data not shown). The HCV-specific IFN-
g, IL-4, and IL-10 responses were caused by CD4+ T cells, as
shown by CD4+ and CD8+ depletion (data not shown).
Statistical analysis. Results were expressed as mean
and analyzed by use of paired and unpaired Student’s t test,SD
x2 test, nonparametric Mann-Whitney U test, Wilcoxon rank
sum test, or Fisher’s exact test, where appropriate, and P !
was considered to be significant. Correlation between dif-.05
ferent parameters was performed by use of Pearson’s or Spear-
man’s rank test. All statistical procedures were performed by
use of SSPS for Windows (version 11; SPSS).
RESULTS
Demographic and clinical characteristics of subjects at base-
line. Subjects with HCV infection alone and subjects with
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Figure 2. Comparison of proliferative responses to hepatitis C virus (HCV) in subjects with HCV infection alone and subjects with coinfection. A,
Comparison of overall proliferative CD4+ cell response to HCV proteins (HCV core, NS3, NS4, and NS5) and control antigen (PHA and TT), as described
in Subjects, Materials, and Methods, expressed as percentage of positive response in the peripheral blood and liver tissue from subjects with chronic
HCV infection alone (black bars), subject with HCV/Schistosoma mansoni coinfection (white bars), and control subjects (shaded bars). Upper panels,
Baseline proliferative responses; lower panels, follow-up proliferative responses. Statistical comparison was performed by use of nonparametric Mann-
Whitney U test. was considered to be significant. B, CD4+ proliferative T cell responses to HCV core, NS3, NS4, and NS5 in peripheral bloodP ! .05
(circles) and liver tissue (squares) from subjects with HCV infection alone (black circles and black squares, respectively) and coinfected subjects (white
circles and white squares, respectively), at baseline (upper panels) and at the end of follow-up (lower panels). Each symbol represents the response
elicited by a given HCV antigen in the proliferation assay. Y-axis, Stimulation index (SI). The cutoff for a positive response is 3 (3 SD above the mean
SI of healthy control subjects). The cutoff for LIL proliferative responses is in relation to proliferative responses from healthy livers. Horizontal lines
represent means. C, Peripheral and intrahepatic HCV-specific cytokine production at baseline and follow-up in subjects with HCV infection alone and
subjects with coinfection: interferon (IFN)–g (black bars), interleukin (IL)–4 (shaded bars), and IL-10 (white bars) production (ELISPOT assay) in peripheral
blood and liver tissue at baseline and follow-up in subjects with HCV infection alone (upper panel) and coinfected subjects (lower panel). X-axis,
tested HCV antigens; Y-axis, significant number of spot-forming cells (sfcs) per 106 LILs or peripheral blood mononuclear cells (PBMCs) (no. of spots
in wells with HCV antigen minus control wells).
coinfection were not significantly different with respect to age,
sex, route or duration of HCV infection, HCV genotype (ge-
notype 4), serum ALT level, histological features (table 1), or
HLA-DRB1 allele distribution. However, throughout the study,
HCV RNA titers were significantly higher in coinfected subjects.
Fibrosis is significantly accelerated in HCV/S. mansoni co-
infection; as expected, coinfected subjects had accelerated liver
fibrosis ( ) (figure 1 and table 2), despite comparableP ! .001
baseline necroinflammatory scores and absence of fibrosis in
subjects with HCV infection alone and subjects with coinfec-
tion. All coinfected subjects had fibrosis scores of 2 at their
follow-up liver biopsies, compared with only 2 subjects with
HCV infection alone (9%) (table 2). At follow-up biopsies,
coinfected subjects had significantly higher degrees of interface
hepatitis ( vs. ; ) and periportal ne-1.5 0.7 0.6 0.5 Pp .027
crosis ( vs. ; ), compared with sub-1.9 0.9 0.9 0.2 Pp .0016
jects with HCV infection alone (data not shown). The mean
( SD) rate of progression of liver fibrosis in the coinfected
subjects was fibrosis units/year, a rate that predicts0.58 0.13
progression to cirrhosis in 10–12 years if progression is linear.
In the subjects with HCV infection alone, the mean ( SD)
rate of progression of liver fibrosis was fibrosis units/0.1 0.06
year, a rate that predicts progression to cirrhosis in 50 years if
progression is linear (figure 1). In subjects with HCV infection
alone and subjects with coinfection, neither ALT levels nor virus
load correlated with the necroinflammatory scores at baseline
or follow-up ( and , respectively, Wilcoxon signedPp .6 Pp .7
rank test). None of the subjects with S. mansoni infection alone
had a necroinflammatory score of 13, and none had fibrosis
at baseline (figure 1). At follow-up biopsy, only 2 (10%) of 20
control subjects with S. mansoni infection alone had progres-
sion of fibrosis, whereas 18 (90%) of 20 remained the same,
suggesting that the enhanced fibrosis in coinfection was not
primarily due to S. mansoni.
HCV-specific CD4+ T cell responses compartmentalize in
the liver with evolution of chronic HCV infection. Our re-
sults revealed differences in frequency, magnitude, and speci-
ficity of peripheral and intrahepatic responses between subjects
with HCV infection alone and subjects with coinfection, at
baseline and follow-up. In general, HCV-specific CD4+ T cell
responses were significantly greater and broader in subjects with
HCV infection alone at both time points (figure 2A, 2B, and
2C and table 3). At baseline, LILs from 15 subjects with HCV
infection alone responded to at least 2 HCV antigens, whereas
LILs from 4 subjects responded to a single antigen (data not
shown). The intrahepatic and peripheral HCV-specific CD4+ T
cell responses to NS3 were significantly stronger than those to
HCV core ( , Wilcoxon signed rank test). Although, atPp .02
the end of follow-up, the peripheral responses waned and be-
came narrowly focused to HCV core in 13 (56.5%) of 23 sub-
jects with HCV infection alone or were lost in 6 (26%) of 23
subjects, HCV-specific CD4+ T cell responses were readily de-
tected in the intrahepatic compartment of 19 of 23 subjects,
although with significantly less magnitude and breadth, com-
pared with baseline (figure 2B and table 3).
In contrast, in 9 coinfected subjects, the baseline responses
in both compartments were weak and narrowly focused, tar-
geting HCV core and/or NS3, whereas 16 subjects did not re-
spond to any of the HCV proteins (figure 2A and 2B). In
general, at baseline, the strength of the intrahepatic proliferative
HCV-specific T cell responses to nonstructural HCV antigens
and HCV core, in LILs, were significantly less in coinfected
subjects (SIcore, ; SINS3, ; SINS4, ; SINS5,4.5 0.3 2.9 1.3 2.5 0.8
) than in subjects with HCV infection alone (baseline:2.3 1.2
SIcore, ; SINS3, ; SINS4, ; SINS5,7.1 3.3 8.3 4.1 3.6 2.5 3
; ). At the end of follow-up, no significant periph-0.8 Pp .002
eral HCV-specific CD4+ T cell responses could be detected in
any coinfected subject, although weak HCV core–specific T cell
proliferative responses were elicited in LILs from 5 coinfected
subjects (20%) (figure 2B and table 3). Despite the poor pro-
liferative response to HCV antigens, coinfected subjects had a
vigorous response to SEA and SWAP that was not significantly
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Table 3. Frequency of hepatitis C virus (HCV)–specific proliferative responses in the intrahepatic and peripheral
compartments, for the 2 groups of patients.
Parameter
Group A:
HCV infection alone
(n p 23)
Group B:
HCV/S. mansoni coinfection
(n p 25)
Baseline End of follow-up Baseline End of follow-up
HCV-specific proliferative responses in PBMCs and LILs 16 (69.6) 13 (56.5) 6 (24) 0 (0)
HCV-specific proliferative responses in LILs only 0 (0) 6 (26.1) 3 (12) 5 (20)
HCV-specific proliferative responses in PBMCs only 3 (13) 0 (0) 0 (0) 0 (0)
Total 19 (82.6) 19 (82.6) 9 (36) 5 (20)
NOTE. Data are no. (%) of subjects. PBMCs, peripheral blood mononuclear cells; S. mansoni, Schistosoma mansoni.
different from the responses in subjects with S. mansoni infec-
tion alone. Moreover, responses to TT or PHA did not differ
among subjects with HCV infection alone, subjects with co-
infection, or control subjects, thus excluding a global T cell un-
responsiveness in coinfected subjects (figure 2A and 2B). This
suggests that infection with S. mansoni specifically inhibited the
HCV-specific CD4+ response in the coinfected subjects. Of note,
depletion assays clearly showed that these are CD4+ T cell re-
sponses (data not shown). It is unlikely that differences between
genotype 1, which was used for the recombinant antigens, and
genotype 4, which infected the patients, are responsible for the
findings, because there is a high degree of conservation between
genotype 1 and genotype 4 proteins in the regions of the re-
combinant proteins used for the immunological assays [22, 23].
Moreover, subjects with acute and chronic infection with HCV
alone, in addition to some coinfected subjects from the study
cohort, had responses to genotype 1 antigens. Baseline virus
load inversely correlated with intrahepatic NS3 and NS4 and
HCV core–specific CD4+ T cell proliferative responses (Rp
and , and , and and0.63 P 1 .05 Rp0.57 P 1 .05 Rp0.5
, respectively; data not shown).P 1 .05
Predominant peripheral and intrahepatic HCV-specific Th1
profile in HCV monoinfection. We then asked if the pe-
ripheral and hepatic cytokine milieu was different in the 2
groups of patients. HCV core–, NS3-, NS4-, and NS5-specific
peripheral and intrahepatic T cells preferentially showed a Th1
cytokine pattern (IFN-g production only) at baseline and fol-
low-up, in subjects with HCV infection alone (figure 2C),
whereas neither IL-4 nor IL-10 could be detected at any time
point. IFN-g production in response to at least 2 HCV antigens
was detected in 10 subjects with HCV infection alone, and IFN-
g production in response to a single antigen was detected in
9 subjects. At follow-up, IFN-g production to NS3 and HCV
core was detected in 4 subjects with HCV infection alone,
whereas, in 15 subjects, IFN-g production was restricted to
either NS3 (6 subjects) or HCV core (9 subjects). Of note, IFN-
g, IL-10, and IL-4 were produced in comparable amounts by
PBMCs and LILs in response to the control antigens (data not
shown). Similar to findings for the CD4+ T cell proliferative
response, coinfected subjects responded poorly to HCV anti-
gens at baseline. Weak production of HCV core–specific IFN-
g alone was detected in LILs from 7 (28%) of 25 subjects,
whereas intrahepatic HCV core–specific IFN-g was detected in
conjunction with IL-10 in 2 (8%) of 25 subjects. IFN-g sfcs
alone were detected from PBMCs in 4 (16%) of 25 coinfected
subjects, whereas IL-10 was produced together with IFN-g in 2
of 25 coinfected subjects. At follow-up, HCV-specific production
of IL-4 and IL-10 was only demonstrated in the intrahepatic
compartment in 7 coinfected subjects (28%), whereas 18 sub-
jects showed no HCV-specific cytokine production (figure 2C),
despite preserved cytokine production in response to schisto-
somal and control antigens. In control subjects with S. mansoni
infection alone, the peripheral and intrahepatic responses to
schistosomal antigens were dominated by Th2 cytokines (IL-4
and IL-10). In the livers of subjects with S. mansoni infection
alone, the levels of S. mansoni–specific IL-4 and IL-10 increased
at the follow-up biopsies, compared with baseline; however, the
increase was statistically significant in 2 of 20 subjects (data
not shown).
The magnitude and pattern of the early HCV-specific CD4+
T cell response predicts the rapidity of progression of fibro-
sis. None of the chronically HCV-infected subjects who had
a 12-point increase in fibrosis score at follow-up biopsies and
rates of progression of fibrosis of 10.25 fibrosis units/year dis-
played any significant intrahepatic CD4+ T cell responses to
HCV at baseline or follow-up (figure 3A). Conversely, no or
slow progression of fibrosis (!2-point increase in follow-up
fibrosis score and a rate of progression of fibrosis of !0.1 fibrosis
units/year) was associated with significant multispecific CD4+
T cell response, particularly to the HCV nonstructural antigens
(figure 3A). There was a significant inverse correlation between
baseline intrahepatic CD4+ T cell proliferative responses against
each of NS3, NS4, HCV core, and NS5 and the rate of progression
of fibrosis ( and , and ,Rp0.72 P ! .01 Rp0.67 P ! .01
and , and and , respec-Rp0.64 P ! .01 Rp0.52 P ! .05
tively); in addition, follow-up proliferative responses against
both NS3 and HCV core inversely correlated with progression
of fibrosis ( and and andRp0.63 P ! .01 Rp0.5 P !
Figure 3. Peripheral and intrahepatic hepatitis C virus (HCV)–specific CD4+ proliferative T cell responses in relation to progression of fibrosis. A,
CD4+ T cell responses to 4 HCV proteins (HCV core, NS3, NS4, and NS5), expressed as stimulation index (SI) (Y-axis), in subjects with a 0–2-point
increase in fibrosis score (left) and subjects with a 12-point increase (right) at the follow-up biopsies. B, Relation of baseline intrahepatic HCV (NS3)
and HCV core–specific CD4+ proliferative T cell responses to progression of fibrosis (fibrosis units per year): the 2 parameters show a significant
inverse correlation ( ; and ; , respectively). C, Relation of follow-up intrahepatic HCV core–specific cytokineRp0.72 P 1 .01 Rp0.64 P 1 .01
production (interferon (IFN)–g, interleukin (IL)–4, and IL-10) to progression of fibrosis (X-axis), expressed as fibrosis units per year. Y-axis, Cytokine
spot-forming cells (sfcs) per 106 LILs. P values were determined by Wilcoxon rank sum test and were considered to be significant at .P ! .05
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, respectively). These findings were confirmed by ELISPOT.05
assay: subjects with more-rapid progression of fibrosis (0.3
fibrosis units/year) had significantly increased intrahepatic pro-
duction of IL-4 and IL-10, with marked suppression of IFN-g
(figure 3C). This pattern occurred in cross-sectional studies of
groups of patients and in longitudinal studies of individual
patients. The association between HCV-specific CD4+ T cell
responses and histological changes shown in the present study
might imply that failure to have sufficient early intrahepatic
HCV-specific CD4+ Th1 response, together with or without an
augmented type-2 response, is associated with more-severe liver
histological assessment and enhanced progression of disease.
DISCUSSION
The effect of the host immune responses in determining hepatitis
C pathogenesis and progression of HCV-related liver fibrosis is
not yet understood. Longitudinal studies correlating the evolu-
tion of these responses with progression of disease are not avail-
able, because of the asymptomatic nature of acute infection and
the protracted course of disease. Studies of chimpanzees suggest
that resolution or persistence of HCV infection depends on the
strength of intrahepatic responses generated at the early stages
of hepatitis [25–27]. Most studies of the HCV-specific CD4+ and
CD8+ T cell responses in humans have focused on the peripheral
blood, because of difficulty in obtaining adequate numbers of
intrahepatic T lymphocytes [21, 29, 30], although it has been
shown that, in chronic infection, HCV-specific CD4+ and CD8+
T cells compartmentalize in the liver [19, 28].
In the present longitudinal prospective study, the availability
of results from paired liver biopsies performed at a very early
phase of chronic evolution and 18 years later enabled us to
monitor the kinetics of intrahepatic CD4+ responses and to
correlate these responses to the progression of liver injury in
subjects who showed slow progression of fibrosis (HCV infec-
tion alone) and subjects who showed rapid progression of fi-
brosis (HCV/S. mansoni coinfection). As previously reported
[11], in our cohort, HCV/S. mansoni coinfection led to ac-
celerated liver fibrosis, with rates of progression of fibrosis of
10.58 fibrosis units/year, compared with the rate of 0.1 fibrosis
units/year seen in the subjects with HCV infection alone, which
are comparable to those in other retrospective studies [7, 24].
Although, to improve uniformity, our subjects were matched
with regard to baseline host and viral factors that might influ-
ence progression of fibrosis, it may be argued that the observed
accelerated progression of fibrosis might be caused by the de-
gree of schistosomiasis or by the additional injury inflicted by
HCV on a liver previously damaged by schistosomiasis. How-
ever, the baseline necroinflammatory and fibrosis scores were
comparable in both groups. Moreover, the control group (sub-
jects with S. mansoni infection alone) did not show significant
necroinflammation, which is in accordance with findings of
previous reports [14–17].
Relevant to our clinical and histological findings, the 2 groups
of patients differed sharply in their CD4+ T cell responsiveness
to HCV. The frequency, magnitude, and breadth of the HCV-
specific T cell responses in subjects with HCV infection alone
were significantly higher than those in coinfected subjects. Our
study has demonstrated a significant inverse association between
intrahepatic CD4+ T cell responses and progression of fibrosis,
suggesting that absent or diminished HCV-specific CD4+ T cell
responses in the liver, particularly during the early phase of
chronic evolution, favor liver damage and progression of disease.
The frequency of baseline intrahepatic HCV-specific T cell re-
sponses in the subjects with HCV infection alone in the present
study is consistent with that in other studies [31], which de-
tected HCV-specific CD4+ T cells in the liver in 78% of subjects
during the early phase of HCV reactivation after liver trans-
plantation. Despite waning or loss of responses in the peripheral
blood over time in both study groups, HCV-specific CD4+ re-
sponses were maintained in the liver, although with less mag-
nitude and breadth, suggesting that the peripheral T cell re-
sponses may not be good indicators of immune responses in
established chronic hepatitis. The discrepancy between liver and
peripheral blood, reflecting compartmentalization of T cells,
may be due to sequestration of HCV-specific T cells in the liver
or homing from the periphery to the liver [33, 34]. Because of
the expansion protocol required for isolation of adequate num-
bers of intrahepatic lymphocytes, the intrahepatic and periph-
eral populations are not directly comparable, but, nonetheless,
distinct patterns emerge. The frequency of intrahepatic CD4+
T cell responses in the subjects with HCV infection alone in
the present study is higher than that reported in other studies
[19, 29, 30], which detected peripheral CD4+ responses in only
one-third of chronically infected subjects. These differences can
likely be explained by the fact that our study detected intrahepatic
responses at a much earlier time point in chronic evolution,
whereas other studies looked only at peripheral responses in
individuals infected for several decades, when most of the re-
sponses compartmentalize in the liver, as shown by reports dem-
onstrating intrahepatic HCV-specificity in 50%–67% of subjects
with long-standing chronic hepatitis C [19, 28, 32]. Interestingly,
coinfected subjects in the present study exhibited selective de-
terioration of HCV-specific Th1 responses while maintaining
normal T cell responses to other antigens, such as TT, PHA, and
schistosomal antigens, thus excluding global T cell unrespon-
siveness. Although we do not yet know the reason for this dis-
crepancy, one may speculate that this is due to the deletion of
more highly activated T cells within the liver [35].
We hypothesized that changes in the intrahepatic cytokine
milieu might play a role in progression of disease. In subjects
with HCV infection alone, intrahepatic and peripheral CD4+
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cells predominantly secreted IFN-g in response to HCV anti-
gens, at baseline and follow-up, which is consistent with find-
ings of published reports [9–11, 19, 29, 30] and demonstrates
predominant Th1 responses in HCV infection. Conversely, co-
infected subjects either displayed no HCV-specific responses or
had type-2 responses, which was associated with a more ad-
vanced disease in those subjects. Studies of mice have shown
that immune deviation to a Th1 response results in decreased
liver fibrosis, whereas enhancement of Th2 cytokine production
promotes an increase in hepatic fibrosis [36, 37]. The associ-
ation of HCV-specific intrahepatic IFN-g production in the
present study with slower progression of fibrosis might be ex-
plained by the findings of several studies that have shown that
IFN-g exhibits direct effects on the synthesis of extracellular
matrix components, particularly the interstitial collagens [38–
40]. In contrast, intrahepatic production of HCV core–specific
IL-4 was only detected in coinfected subjects with high rates
of progression of fibrosis (0.3), which is in line with findings
of previous reports demonstrating the potential role of this
cytokine in driving the differentiation of CD4+ T cells into the
Th2 subset and generation of hepatic fibrosis [14, 15, 41, 42].
Collectively, our data suggest that alterations of cytokine pat-
terns in the form of insufficient intrahepatic Th1 responses or
augmented Th2 responses enhance progression of fibrosis. Al-
though, in the present study, we were able to examine only a
limited number of cytokines, because of restrictions on the
numbers of cells available for these assays, studies evaluating
the role of other proinflammatory and profibrogenic cytokines
constitute an important area for future research.
In conclusion, the data presented in the present study have
demonstrated for the first time the importance of cellular im-
mune responses in preventing the progression of liver disease
and have illustrated that absence or decline of type-1 CD4+ T
cell responses during the early phases of chronic HCV may
lead to greater progression of liver disease. Our findings may
have implications for development of a vaccine and immu-
notherapy. Given the quasi-species nature of HCV, it likely will
be difficult to formulate a vaccine that effectively protects 100%
of exposed individuals. However, our data suggest that, even
without sterilizing immunity, a vaccine that induces strong cel-
lular immune responses might limit subsequent liver damage.
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